Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C24H39NaO4
CAS Number:
Molecular Weight:
414.55
NACRES:
NA.25
PubChem Substance ID:
UNSPSC Code:
12161900
MDL number:
description
anionic
Quality Level
assay
≥97%
form
powder
mol wt
414.55 g/mol
technique(s)
protein purification: suitable
SMILES string
[Na].[H][C@@]12C[C@H](O)CC[C@]1(C)[C@@]3([H])CC[C@]4(C)[C@]([H])(CC[C@@]4([H])[C@]3([H])[C@H](O)C2)[C@H](C)CCC(O)=O
InChI
1S/C24H40O4.Na.H/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26;;/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28);;/t14-,15+,16-,17-,18+,19+,20-,22+,23+,24-;;/m1../s1
InChI key
WANBNZVOEKGHSS-VQNKLXGESA-N
General description
Sodium chenodeoxycholate is a bile salt, which has been shown to accelerate colonic transit and improve bowel function.
Application
Sodium chenodeoxycholate has been used in a study to assess DNA repair response in the bacterium Escherichia coli. It has also been used in a study to investigate the physical and chemical factors influencing germination of Clostridium difficile spores.
Biochem/physiol Actions
Bile Salt
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Repr. 2
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
L J Wheeldon et al.
Journal of applied microbiology, 105(6), 2223-2230 (2009-01-06)
To investigate the influence of chemical and physical factors on the rate and extent of germination of Clostridium difficile spores. Germination of C. difficile spores following exposure to chemical and physical germinants was measured by loss of either heat or
V Vanhoorne et al.
Orphanet journal of rare diseases, 14(1), 186-186 (2019-08-03)
Pharmaceutical compounding of orphan active ingredients can offer cost-effective treatment to patients when no other drug product is available for a rare disease or during periods of drug product shortages. Additionally, it allows customized therapy for patients with rare diseases.
Tina Kauss et al.
Journal of pharmaceutical sciences, 108(8), 2805-2813 (2019-03-18)
Current pediatric antibiotic therapies often use oral and parenteral routes of administration. Neither are suitable for treating very sick neonates who cannot take oral medication and may be several hours away from hospital in developing countries. Here, we report on
Global Trade Item Number
| SKU | GTIN |
|---|---|
| C8261-1G | 04061833521984 |
| C8261-500MG | 04061833619117 |

